Antibodies to plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria

Pediatric Infectious Disease Journal

Volumn 30, Issue 12, 2011, Pages 1037-1042

  McCarra, Matthew B ^a   Ayodo, George ^b   Sumba, Peter O ^b   Kazura, James W ^c   Moormann, Ann M ^d   Narum, David L ^e   John, Chandy C ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

children; EBA 175; holoendemic; malaria

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; ERYTHROCYTE BINDING ANTIGEN 175; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MEROZOITE SURFACE PROTEIN 1; PARASITE ANTIGEN; PROTOZOON ANTIBODY; UNCLASSIFIED DRUG;

ACCURACY; ANTIBODY TITER; ARTICLE; CHILD; ENDEMIC DISEASE; EXPOSURE; HUMAN; INFANT; KENYA; MAJOR CLINICAL STUDY; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOGLOBULIN G; INFANT; KAPLAN-MEIER ESTIMATE; KENYA; MALARIA, FALCIPARUM; MEMBRANE PROTEINS; MEROZOITE SURFACE PROTEIN 1; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RISK FACTORS;

EID: 81855175965     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31822d1451     Document Type: Article

References (47)

1. Aregawi M, Cibulskis R, Kita Y, et al. World Malaria Report 2010.Geneva, Switzerland: World Health Organization; 2010:90-92.
2. Cohen S, McGregor IA, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature. 1961;192:733-737.
3. McGregor IA. The passive transfer of human malarial immunity. Am J Trop Med Hyg. 1964;13:237-239.
4. Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol. 2006;28:51-60.
5. Good MF. Towards a blood-stage vaccine for malaria: are we following all the leads? Nature Rev. 2001;1:117-125. (Pubitemid 33741965)
6. Stanisic DI, Richards JS, McCallum FJ, et al. Immunoglobulin G subclassspecific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun. 2009;77:1165-1174.
7. Nebie I, Diarra A, Ouedraogo A, et al. Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Infect Immun. 2008;76:759-766. (Pubitemid 351251748)
8. Polley SD, Mwangi T, Kocken CH, et al. Human antibodies to recombinant protein constructs of Plasmodium falciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine. 2004;23:718-728. (Pubitemid 39473204)
9. Fowkes FJ, Richards JS, Simpson JA, et al. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis. PLoS Med. 2010;7:e1000218.
10. Murhandarwati EE, Wang L, Black CG, et al. Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Vietnam. Infect Immun. 2009;77:4510-4517.
11. Kitua AY, Urassa H, Wechsler M, et al. Antibodies against Plasmodium falciparum vaccine candidates in infants in an area of intense and perennial transmission: relationships with clinical malaria and with entomological inoculation rates. Parasite Immunol. 1999;21:307-317. (Pubitemid 29257759)
12. Nwuba RI, Sodeinde O, Anumudu CI, et al. The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies. Infect Immun. 2002;70:5328-5331.
13. Dodoo D, Aikins A, Kusi KA, et al. Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children. Malar J. 2008;7:142.
14. Branch OH, Udhayakumar V, Hightower AW, et al. A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. Am J Trop Med Hyg. 1998;58:211-219. (Pubitemid 28096229)
15. Richards JS, Stanisic DI, Fowkes FJ, et al. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis. 2010;51:e50-e60.
16. Osier FH, Fegan G, Polley SD, et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun. 2008;76:2240-2248. (Pubitemid 351656161)
17. John CC, Moormann AM, Sumba PO, et al. Gamma interferon responses to Plasmodium falciparum liver-stage antigen 1 and thrombospondin-related adhesive protein and their relationship to age, transmission intensity, and protection against malaria. Infect Immun. 2004;72:5135-5142. (Pubitemid 39223398)
18. John CC, Tande AJ, Moormann AM, et al. Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children. J Infect Dis. 2008;197:519-526. (Pubitemid 351321528)
19. Kaslow DC HG, Kumar S,. Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1(19)) variants secreted from Saccharomyces cerevisiae. Mol Biochem Parasitol. 1994:283-289.
20. John CC, Moormann AM, Pregibon DC, et al. Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. Am Trop Med Hyg. 2005;73:222-228. (Pubitemid 41278777)
21. Okenu DM, Riley EM, Bickle QD, et al. Analysis of human antibodies to erythrocyte binding antigen 175 of Plasmodium falciparum. Infect Immun. 2000;68:5559-5566.
22. Ohas EA, Adams JH, Waitumbi JN, et al. Measurement of antibody levels against region II of the erythrocyte-binding antigen 175 of Plasmodium falciparum in an area of malaria holoendemicity in western Kenya. Infect Immun. 2004;72:735-741. (Pubitemid 38166650)
23. Vera-Bravo R, Valbuena JJ, Ocampo M, et al. Amino terminal peptides from the Plasmodium falciparum EBA-181/JESEBL protein bind specifically to erythrocytes and inhibit in vitro merozoite invasion. Biochimie. 2005;87:425-436. (Pubitemid 40488371)
24. O'Donnell RA, Hackett F, Howell SA, et al. Intramembrane proteolysis mediates shedding of a key adhesin during erythrocyte invasion by the malaria parasite. J Cell Biol. 2006;174:1023-1033
25. Narum DL, Haynes JD, Fuhrmann S, et al. Antibodies against the Plasmodium falciparum receptor binding domain of EBA-175 block invasion pathways that do not involve sialic acids. Infect Immun. 2000;68:1964-1966. (Pubitemid 30164824)
26. Sim BK, Orlandi PA, Haynes JD, et al. Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion. J Cell Biol. 1990;111:1877-1884.
27. Jones TR, Narum DL, Gozalo AS, et al. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. J Infect Dis. 2001;183:303-312. (Pubitemid 32066033)
28. Florens L, Washburn MP, Raine JD, et al. A proteomic view of the Plasmodium falciparum life cycle. Nature. 2002;419:520-526.
29. Silvie O, Franetich JF, Charrin S, et al. A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem. 2004;279:9490-9496. (Pubitemid 38296016)
30. Sim BK, Narum DL, Luu T, et al. Delineation of stage specific expression of Plasmodium falciparum EBA-175 by biologically functional region II monoclonal antibodies. In press.
31. Sim BK, Chitnis CE, Wasniowska K, et al. Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science. 1994;264: 1941-1944. (Pubitemid 24245642)
32. al-Yaman F, Genton B, Kramer KJ, et al. Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. Am J Trop Med Hyg. 1996;54:443-448. (Pubitemid 26162236)
33. Dodoo D, Theander TG, Kurtzhals JA, et al. Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. Infect Immun. 1999;67:2131-2137. (Pubitemid 29200463)
34. John C, O'Donnell R, Sumba P, et al. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-119) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J Immunol. 2004.
35. Gray JC, Corran PH, Mangia E, et al. Profiling the antibody immune response against blood stage malaria vaccine candidates. Clin Chem. 2007;53:1244-1253. (Pubitemid 47020980)
36. Gupta S, Snow RW, Donnelly CA, et al. Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat Med. 1999;5:340-343. (Pubitemid 29124373)
37. Corran PH, O'Donnell RA, Todd J, et al. The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton merozoite surface protein 1-specific antibodies is associated with resistance to malarial parasitemia in a cross-sectional survey in The Gambia. Infect Immun. 2004;72:6185-6189. (Pubitemid 39303741)
38. Okech BA, Corran PH, Todd J, et al. Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia. Infect Immun. 2004;72:1557-1567. (Pubitemid 38263778)
39. Osier FH, Weedall GD, Verra F, et al. Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya. Infect Immun. 2010;78:4625-4633.
40. Mehrizi AA, Zakeri S, Salmanian AH, et al. IgG subclasses pattern and high-avidity antibody to the C-terminal region of merozoite surface protein 1 of Plasmodium vivax in an unstable hypoendemic region in Iran. Acta Trop. 2009;112:1-7.
41. Wickramarachchi T, Illeperuma RJ, Perera L, et al. Comparison of naturally acquired antibody responses against the C-terminal processing products of Plasmodium vivax merozoite surface protein-1 under low transmission and unstable malaria conditions in Sri Lanka. Int J Parasitol. 2007;37:199-208. (Pubitemid 46074017)
42. Taylor RR, Allen SJ, Greenwood BM, et al. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg. 1998;58:406-413. (Pubitemid 28183248)
43. Aribot G, Rogier C, Sarthou JL, et al. Pattern of immunoglobulin isotype response to Plasmodium falciparum blood-stage antigens in individuals living in a holoendemic area of Senegal (Dielmo, west Africa). Am J Trop Med Hyg. 1996;54:449-457.
44. Ferreira MU, Kimura EA, Katzin AM, et al. The IgG-subclass distribution of naturally acquired antibodies to Plasmodium falciparum, in relation to malaria exposure and severity. Ann Trop Med Parasitol. 1998;92:245-256. (Pubitemid 28230513)
45. Bouharoun-Tayoun H, Druilhe P. Antibodies in falciparum malaria: what matters most, quantity or quality? Mem Inst Oswaldo Cruz. 1992;87(suppl 3):229-234.
46. Ndungu FM, Bull PC, Ross A, et al. Naturally acquired immunoglobulin (Ig)G subclass antibodies to crude asexual Plasmodium falciparum lysates: evidence for association with protection for IgG1 and disease for IgG2. Parasite Immunol. 2002;24:77-82. (Pubitemid 34225276)
47. Clark TD, Greenhouse B, Njama-Meya D, et al. Factors determining the heterogeneity of malaria incidence in children in Kampala, Uganda. J Infect Dis. 2008;198:393-400.